Sino Medical Sciences Technology Inc., (SHA: 688108) a leading China-based medical device company, has announced that its HT Supreme drug-eluting stent system has received market approval in Brazil. This system is designed to improve the diameter of the coronary artery lumen in patients suffering from symptomatic heart disease caused by primary coronary artery lesions, with a reference vessel diameter of 2.25-5.00mm .
Product Description and Innovation
The HT Supreme drug-coated coronary artery stent system is a cutting-edge drug-device combination product. It comprises a drug-coated expandable cobalt chromium (CoCr) alloy coronary artery stent and a balloon delivery system. The stent’s scaffold is coated with a non-corrosive polymer layer at the bottom, and the surface is coated with a biodegradable polymer layer for drug release. The drug release mechanism involves a mixture of sirolimus and biodegradable polymers, which is delivered using a rapid exchange balloon expandable conveying system .
Global Registration and Market Impact
The HT Supreme stent system has already been registered in several countries, including Thailand, Singapore, Indonesia, Turkey, Taiwan, and the European Union. Its recent approval in Brazil further expands its global footprint. The product also secured a position in the continuous national volume-based procurement (VBP) of coronary stents in China upon agreement expiration in December 2022, highlighting its competitive edge in the market .- Flcube.com
